Riik: Iisrael
keel: inglise
Allikas: Ministry of Health
FLUOROURACIL; SALICYLIC ACID
NEOPHARM LTD
D11AF
SOLUTION
SALICYLIC ACID 10 G / 100 G; FLUOROURACIL 0.5 G / 100 G
TOPICAL
Required
ALMIRALL HERMAL GMBH, GERMANY
WART AND ANTI-CORN PREPARATIONS
Common warts ( special form : plantar warts, on areas of the sole of the foot that are subjected to pressure), plane juvenile warts of the extremities.
2020-10-31
1 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed with a doctor’s prescription only VERRUMAL SOLUTION Solution for topical application ACTIVE INGREDIENTS: Each 100 gr contain: Fluorouracil 0.5 gr Salicylic acid 10 gr For the list of inactive ingredients and allergens in the medicinal product, see section 6. READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, consult with your doctor or pharmacist. IT IS RECOMMENDED TO READ THIS LEAFLET WITH ANOTHER FAMILY MEMBER. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. 1. WHAT IS THIS MEDICINE INTENDED FOR? For the treatment of common warts (warts beneath the soles of the feet in areas where pressure is applied to the soles of the feet) and flat warts on hands and feet. THERAPEUTIC GROUP: anti-wart and keratolytic agents. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE: – if you are sensitive/allergic to the active ingredients, fluorouracil or salicylic acid (salicylates), or to any of the other ingredients of this medicine that are listed in section 6. – if you are breastfeeding. – if you are pregnant or if there is a concern that you may be pregnant. – to treat infants. – on patients suffering from renal insufficiency. – if you are undergoing treatment for chickenpox and/or for herpes zoster; if you took brivudine, sorivudine and/or their derivatives (antiviral medicines for the treatment of herpes zoster). The active ingredient, fluorouracil, concomitantly with brivudine, sorivudine or their derivatives, may significantly exacerbate the side effects of Verrumal. Treatment with Verrumal may be started, at the very earliest, four weeks after completing the treatment for herpes zoster with brivudine or sorivudine. If you are being treated or were recently tr Lugege kogu dokumenti
1 VERRUMAL® 1. NAME OF THE MEDICINAL PRODUCT Verrumal Solution Solution, topical Fluorouracil, Salicylic acid 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 100 g of solution contains: Fluorouracil 0.5 g; salicylic acid 10.0 g Other excipient with known effect: dimethyl sulfoxide 8.0 g and 160 mg alcohol (ethanol) per g. For a full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM Solution, topical. Verrumal Solution is a clear, colourless to slightly yellow-orange solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Common warts (special form: plantar warts, on areas of the sole of the foot that are subjected to pressure), plane juvenile warts of the extremities. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Generally Verrumal Solution is applied to every wart two to three times daily. The average duration of treatments is six weeks. It must be applied consistently every single day. After successful treatment further treatment should follow for approx. one week. Children Verrumal Solution must not be used on babies. Method of administration For application to the skin. Verrumal Solution must only be used on the wart and not on the healthy skin around the wart; if necessary, cover the surrounding skin with a paste or cream. It is recommended that wipe the brush on the neck of the bottle before dabbing it on. With very small warts you should use a toothpick or something instead of a brush for more precise application. 2 Before reapplying Verumal Solution the coating should be removed every time by simply pulling it off. In case of periungual and in particular subungual warts, make sure that the nail matrix is not damaged and that Verrumal Solution does not get into the nail bed. The area to be treated should not be larger than 25 cm². Experience has shown that in many cases, e.g. with very prominent common warts and planar warts on the soles of the feet, it is better if the dead tissue is removed by a doctor after treatment with Verrumal Solu- tion. 4.3 CONTRAINDICATIONS Hypersensitivity to Lugege kogu dokumenti